Facioscapulohumeral Muscular Dystrophy
·MeSH: Muscular Dystrophy, Facioscapulohumeral
Prevalence
30.0 / 100K
4 drugs in development·4 companies·3 clinical trials
Drug Pipeline by Phase
Phase 3(3)
Phase 2(1)
| Drug | Company |
|---|---|
| apitegromab | Scholar Rock Holding Corp (SRRK) |
Compare drugs
Frequently asked questions
How many drugs are in development for Facioscapulohumeral Muscular Dystrophy?
BioSniper tracks 4 drugs in development for Facioscapulohumeral Muscular Dystrophy across 4 companies.
How many clinical trials target Facioscapulohumeral Muscular Dystrophy?
There are 3 clinical trials targeting Facioscapulohumeral Muscular Dystrophy tracked by BioSniper.
What is the prevalence of Facioscapulohumeral Muscular Dystrophy?
The estimated prevalence of Facioscapulohumeral Muscular Dystrophy is approximately 30.0 per 100,000 population.
Deep-dive into Facioscapulohumeral Muscular Dystrophy
Full trial data, competitive analysis, and AI-powered pipeline tracking.
Start Free Analysis